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1Introduction
Nonribosomal peptides (NRPs) and polyketides (PKs) 
are two major classes of secondary metabolites with im-
portant therapeutic properties, such as antibiotic, anti-
fungal, immunosuppressive, or antitumor activities. They 
are produced in bacteria and fungi by multimodular 
enzymatic assembly lines, known as nonribosomal peptide 
synthetases (NRPSs) and polyketide synthases (PKSs), 
respectively (Finking and Marahiel 2004; Smith and Tsai 
2007). Due to similarities in their modular organization 
and biosynthetic strategies, PKSs and NRPSs are able to 
assemble into hybrid multienzyme complexes (Du et al. 
2001). Kalimantacin, an antibiotic produced by 
Pseudomonas fluorescens BCCM_ID9359, is produced by 
such a hybrid NRPS- PKS system and its biosynthetic 
pathway has been fully elucidated (Fig. 1) (Mattheus 
et al. 2010a). The kalimantacin enzymatic assembly line 
is composed of three polypeptides (Bat1, Bat2, and Bat3), 
harboring 11 trans- acyltransferase (AT) PKS modules and 
one NRPS module. The latter incorporates glycine into 
the PK backbone and is situated in the first module of 
Bat2 (Bat2mod1). During and after assembly line bio-
synthesis, kalimantacin is modified by several trans- acting 
tailoring enzymes (Fig. 1) (Mattheus et al. 2010a). 
Kalimantacin exerts strong antagonistic activity against 
staphylococci (MIC 0.05 μg/mL) and has moderate activ-
ity against enterobacteria (MIC 1–10 μg/mL). It acts by 
inhibiting the trans- 2- enoyl- acyl carrier protein (ACP)- 
reductase (FabI), an enzyme responsible for the final 
step in bacterial fatty acid biosynthesis (Mattheus et al. 
2010b).
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Abstract
Kalimantacin is an antimicrobial compound with strong antistaphylococcal 
 activity that is produced by a hybrid trans- acyltransferase polyketide synthase/
nonribosomal peptide synthetase system in Pseudomonas fluorescens 
BCCM_ID9359. We here present a systematic analysis of the substrate specificity 
of the glycine- incorporating adenylation domain from the kalimantacin biosyn-
thetic assembly line by a targeted mutagenesis approach. The specificity- conferring 
code was adapted for use in Pseudomonas and mutated adenylation domain 
active site sequences were introduced in the kalimantacin gene cluster, using a 
newly adapted ligation independent cloning method. Antimicrobial activity screens 
and LC- MS analyses revealed that the production of the kalimantacin analogues 
in the mutated strains was abolished. These results support the idea that further 
insight in the specificity of downstream domains in nonribosomal peptide 
 synthetases and polyketide synthases is required to efficiently engineer these 
strains in vivo.
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Nonribosomal peptide synthetases (NRPS) modules typi-
cally consist of a condensation (C) domain for peptide 
bond formation, an adenylation (A) domain for selection 
and activation of the cognate amino acid (AA) building 
block and a thiolation (T) domain or peptidyl carrier 
protein (PCP) that covalently tethers the growing inter-
mediate to the enzyme complex (Finking and Marahiel 
2004). NRPs exhibit a high structural diversity, which is 
partly determined by the substrate specificity of the A 
domains (Lautru and Challis 2004). Aside from the 22 
proteinogenic AA, A domains can additionally introduce 
nonproteinogenic AAs and α- hydroxy acids as well as 
nonsubstituted carboxylic acids. The substrate- binding 
pocket of A domains is lined by 10 AA residues that 
determine the nature of the AA that is incorporated into 
the NRP backbone. This specificity- conferring code can 
be bioinformatically extracted and enables the structure 
prediction of new NRPs based on the genomic arrange-
ment of the corresponding biosynthetic genes (Stachelhaus 
et al. 1999; Challis et al. 2000; Röttig et al. 2011). This 
has already been exploited to rationally alter the specificity 
of A domains by targeted mutagenesis. So far, only rela-
tively small changes in A domain specificity, for example, 
Asp to Asn, Glu to Gln, Phe to Tyr, have been achieved 
in in vitro experiments with purified mutant A domains 
(Stachelhaus et al. 1999; Eppelmann et al. 2002; Stevens 
et al. 2006). Recently, the Phe- incorporating A domain of 
gramicidin synthetase (GrsA) has been successfully re- 
engineered to introduce azide- and alkyne- substituted AA 
(Kries et al. 2014). Attempts to drastically change the 
substrate specificity have resulted in a decrease in the A 
domain activity (Chen et al. 2009). In vivo efforts to create 
NRP analogues with variations in AA composition by tar-
geted mutagenesis of A domains appear to be even more 
challenging (Eppelmann et al. 2002; Uguru et al. 2004; 
Han et al. 2012; Thirlway et al. 2012). In this study, we 
attempted to rationally and systematically change the speci-
ficity of the glycine- incorporating A domain in the NRPS 
module of the kalimantacin biosynthetic assembly line by 
using a new targeted mutagenesis approach and a specificity- 
conferring code designed for use in Pseudomonas. The 
functionality and specificity of the  mutated A domains 
were subsequently analyzed by ultrahigh- resolution LC- MS 
analysis of culture supernatants.
Experimental Procedures
Bacterial strains and culture conditions
Pseudomonas fluorescens BCCM_ID9359 was used for wild- 
type kalimantacin production and was grown in tryptose 
broth (Merck) or tryptose agar (tryptose broth supple-
mented with 1.5% w/v agar) at 30°C (Mattheus et al. 
2010a). Escherichia coli Top10 (Invitrogen™, Carlsbad, CA) 
was used for amplification of plasmids and cloning pur-
poses, whereas E. coli S17- 1 (Simon et al. 1983) was used 
for conjugational transfer to P. fluorescens BCCM_ID9359. 
All E. coli strains were grown in lysogeny broth (LB) or 
Figure 1. Biosynthetic pathway and structure of kalimantacin. Biosynthesis of kalimantacin is initiated in the loading module by the trans-acting 
acyltransferase BatH, which loads an acetyl-CoA unit onto the first ACP. A second trans-AT, BatJ, selectively delivers malonyl-CoA to the 11 remaining 
PKS-modules in the biosynthetic pathway. The NRPS-module in Bat2 incorporates a glycine residue into the growing intermediate. BatA-E, BatK, BatF, 
and BatM perform several on- and post-PKS tailoring reactions to produce the final bioactive compound. KS, ketosynthase; KR, ketoreductase; DH, 
dehydratase; ACP, acyl carrier protein; MT, methyltransferase; C, condensation domain; A, adenylation domain; PCP, peptidyl carrier protein; TE, 
thioesterase; AA, amino acid.
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LB agar (LB broth with 1.5% w/v agar) at 37°C. Strains 
used in this study are listed in Table S2.
Construction of adenylation domain 
mutants
Plasmids and primers used in this study are listed in Table 
S2. First 5′ and 3′ flanking regions of the adenylation 
 domain active site sequence were amplified with tailed 
primers introducing restriction sites and these fragments 
were restricted and ligated into pUC18 using T4 DNA ligase 
(Thermo scientific) following the manufacturer’s  protocols. 
The sequence of this construct was verified as described 
below. The mutated active site fragments were chemically 
synthesized at Integrated DNA Technologies (Haasrode, 
Belgium) and amplified for ligation independent cloning 
by pfu DNA polymerase (Thermo scientific, Waltham, MA).
The ligation independent cloning method was adapted 
from Thieme et al. (2011). First, the pUC18 plasmid with 
5′ and 3′ fragment was treated with PstI. A mixture of 
this linearized plasmid, the amplified synthetic DNA frag-
ment, and T4 DNA polymerase was incubated for 5 min 
at 25°C, immediately followed by transformation of E. coli 
Top10. The sequence of the resulting plasmids was veri-
fied by sequence analysis. The complete 5′–3′ construct 
with adapted adenylation domain sequence was then 
transferred from pUC18 to suicide plasmid pAKE604 (El- 
Sayed et al. 2003) by regular restriction and ligation and 
again verified by sequence analysis.
To easily detect mutated active site introduction, a 
plasmid containing the 5′ and 3′ flanking sequences was 
constructed, flanking the gentamicin resistance gene. All 
fragments were amplified by tailed primers introducing 
restriction sites (as listed in Table S2). After restriction, 
they were ligated using T4 DNA ligase. The construct 
was verified by sequence analysis. This construct was in-
troduced in the genome of P. fluorescens BCCM_ID9359 
by biparental conjugation with E. coli S17- 1. Both strains 
were grown to late exponential phase and mixed on a 
sterile 0.45 μm Millipore filter on tryptose agar. After 
overnight incubation, the filter was washed with 1 mL 
0.9% sodium chloride and plated on tryptose agar sup-
plemented with kanamycin and triclosan to select for 
vector integration by a first crossover event. Next, colonies 
were incubated overnight in tryptose broth without any 
selection to enable vector excision and plated in serial 
dilutions on tryptose agar with 5% w/v sucrose. Colonies 
were then checked by replica plating on tryptose agar 
with gentamicin and tryptose agar with kanamycin. 
Gentamicin- resistant, but kanamycin- sensitive clones were 
verified by PCR with primers external of the 5′ and 3′ 
flanking region and the amplified region was then verified 
by sequence analysis.
Finally, to introduce the mutated active site sequence, 
the gentamicin- resistant strain was used for another round 
of biparental conjugation with the mutated active site 
constructs in pAKE604 in E. coli S17- 1. The same strategy 
was used as described above, selecting at the end for 
gentamicin- sensitive clones. Again, the genome of the 
strain was verified by PCR with the external primers, 
followed by sequencing of this PCR product.
Sequence analysis of plasmids and genomic 
regions
Plasmids or PCR fragments of genomic regions were used 
in a Sanger sequencing reaction with Big Dye terminator 
mix (Applied biosystems, Waltham, MA) and the resulting 
mixture was purified by ethanol precipitation. Samples 
were run on an ABI 3130 genetic analyzer (Applied bio-
systems) and analyzed using Sequencer 4.8 software 
(GeneCodes Inc, Ann Arbor, MI).
Bioassay of strains and extracts
After large- scale fermentation in 500 mL cultures, kali-
mantacin and analogues were extracted with chloroform, 
as described by Mattheus et al. (2010a). The activity of 
the extracts was tested by spotting 2 μL of the extract 
on a lawn of Staphylococcus aureus ATCC27661 in station-
ary phase, diluted to an optical density at 600 nm of 
0.03. Results were recorded after 12 h of incubation at 
37°C. The activity of the mutant strains was evaluated 
by spotting 2 μL of an overnight culture on a similar 
lawn of S. aureus ATCC27661. Plates were incubated for 
48 h at 16°C, followed by 12 h at 37°C.
LC/MS analysis of kalimantacin production
After 24 h at 16°C, followed by 12 h at 4°C, the pH of 
50 mL fermentation cultures was adjusted to pH 10 with 
formic acid. After centrifugation, 2 μL of the  supernatant 
was analyzed directly with LC- MS (column: Agilent Zorbax 
Eclipse RP- C18, 100 × 2.1 mm, 1.8 μm). A Bruker MaXis 
Impact Q- TOF mass spectrometer coupled with a Dionex 
3000RS UHPLC was used. Mobile phases consist of A, 
water with 0.1% formic acid, and B, acetonitrile with 
0.1% formic acid. After the initial 5 min of isocratic run 
at 5% B, a gradient of 5B–100% B in 18 min, then 
isocratic at 100% B for 5 min was employed with flow 
rate at 0.2 mL/min; UV was set at 210 nm. The mass 
spectrometer was operated in electrospray positive mode 
with a scan range of 50–3000 m/z. Source conditions are: 
end plate offset at −500 V; capillary at −4500 V; nebulizer 
gas (N2) at 1.4 bar; dry gas (N2) at 8 L/min; dry tem-
perature at 180°C. Ion transfer conditions as, ion funnel 
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1 RF at 200 Vpp; ion funnel 2 RF at 200 Vpp, hexapole 
RF at 200 Vpp; quadruple ion energy at 5 ev, quadrupole 
low mass set at 55 m/z; collision energy at 5.0 ev; colli-
sion RF ramping from 800 to 1500 Vpp; transfer time 
set from 100 to 155 μsec; pre- Pulse storage time set at 
5 μsec. Calibration was done with sodium formate 
(10 m mol/L) through a loop injection of 20 μL of stand-
ard solution at the beginning of each run.
Results
Generation of a Pseudomonas- specific 
specificity- conferring code
Research into the specificity- conferring code of A 
 domains has revealed that genus- specific variations exist 
at specific positions in the code (Challis et al. 2000), 
which hint at “wobble- like” positions (Stachelhaus et al. 
1999). Therefore, we hypothesized that the specificity 
of mutated A domains can be improved by the use 
of a genus- specific code. A literature wide study was 
performed, searching for NRPSs with characterized 
products in Pseudomonas spp. and the different 
specificity- conferring codes of the A domains were 
extracted using NRPSpredictor2 (Table S1) (Röttig et al. 
2011). Since all of these codes were derived from 
Pseudomonas sequences, they were considered 
Pseudomonas specific, or at least compatible. For each 
position in the specificity- conferring code, the most 
commonly encountered AA was selected and preference 
was given to AAs present in A domains from NRPSs 
in P. fluorescens spp. As such, 10 specificity- conferring 
codes were designed with the aim of replacing Gly in 
the final structure of kalimantacin with 10 alternative 
AAs, namely Ala, Leu, Val, Ser, Cys, Arg, Asp, Gln, 
Phe, and Pro, representing different natural AA classes 
(Table 1).
Ligation independent cloning enables 
efficient introduction of mutated active site 
fragments
To introduce these adapted specificity- conferring codes 
in the A domain of Bat2mod1, the positions of the 10 
AAs in Bat2mod1 that comprise the original code were 
identified by sequence alignments with the archetypic 
GrsA (Stachelhaus et al. 1999; Challis et al. 2000). Taking 
into account the codon usage of Pseudomonas protegens 
Pf5, DNA fragments encoding the altered specificity- 
conferring codes were designed. The specificity of these 
A domains was verified with NRPSpredictor2, using the 
nearest neighbor method (Röttig et al. 2011). All codes 
were predicted to introduce the intended AA with a 
score of 90%, except for Gln, which would be introduced 
with a predicted score of 60%. Chemically synthesized 
gene fragments containing the correct mutations were 
cloned into a pUC18 (Invitrogen™) plasmid, containing 
the two flanking regions (±350 base pairs (bp) and 
500 bp) of the mutated active site, using an adapted 
ligation independent cloning approach. An overlap of 
12 bp between the flanking fragments and the synthetic 
DNA fragment allowed efficient ligation independent 
cloning, as illustrated in Figure 2 (Thieme et al. 2011). 
Following sequence analysis, the complete fragment, 
comprising the 5′ and 3′ flanking regions and the  mutated 
active site sequence, was transferred to suicide vector 
pAKE604 (El- Sayed et al. 2003) via regular restriction 
and ligation.
Table 1. Overview of adapted specificity- conferring codes for use in Pseudomonas. AA positions and the corresponding specificity- conferring codes 
of the Phe- incorporating A domain in GrsA and the Gly- incorporating A domain in Bat2mod1 are illustrated. Codes were predicted by comparative 
analysis of A domain from different Pseudomonas NRPSs.
AA1 AA2 AA3 AA4 AA5 AA6 AA7 AA8 AA9 AA10
235 236 239 278 299 301 322 330 331 517
Phe grsA D A W T I A A I C K
Gly bat2 D I L Q L G L I W K
701 702 705 744 767 769 791 799 800 –
Ala D L Y N N A L T Y K
Leu D A W F L G N V V K
Val D A L W I G G T F K
Ser D V W H M S L V D K
Gln D A W Q V G V V D K
Cys D L Y N L S P I W K
Arg D V A D V G A I D K
Phe D A P I M G G T C K
Asp D S W K L G V V D K
Pro D V Q Y I A H V V K
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To facilitate the introduction of the mutated active site 
sequences in bat2 in P. fluorescens BCCM_ID9359, the 
400 bp genomic fragment, targeted for mutation, was first 
replaced by a gentamicin resistance cassette via double 
homologous recombination. Next, the vector carrying the 
mutated active site and flanking regions was introduced 
into this gentamicin- resistant P. fluorescens mutant via 
conjugation and a first crossover event, enabling exchange 
of the resistance cassette with the active site via a second 
crossover event.
PCR and sequence analysis of the constructed plasmids 
revealed a very high efficiency for the ligation- independent 
cloning method (80–95%). Recombination of these plas-
mids and the gentamicin- resistant strains, using 5′ 350 bp 
and 3′ 500 bp homologous regions, resulted in one 
gentamicin- sensitive clone out of five tested clones. 
Sequence analysis of these strains indicated that all 
gentamicin- sensitive strains had incorporated the mutated 
active site sequence without errors. As a positive control, 
the WT active site sequence was also reintroduced in the 
gentamicin- resistant strain.
Bioassay and LC- MS analyses show the 
absence of production of kalimantacin 
analogues
Bioassays with the mutant strains and the crude extracts 
of large- scale fermentations on a lawn of S. aureus 
ATCC27661 cells revealed a clear decrease in activity for 
all of the mutants, comparable to the activity of the batC 
deletion mutant, which no longer produces kalimantacin, 
and its extract (Mattheus et al. 2010a). The positive control 
showed WT activity again (Fig. 3). To determine if the 
decrease in activity is due to low or abolished antibiotic 
production or to production of an inactive kalimantacin 
analogue, culture supernatants were analyzed by ultrahigh- 
resolution LC- MS. In the supernatant of the WT sample, 
the m/z value corresponding to the WT mass could be 
easily detected. The noise level was in the 100–200 counts 
range. However, in the supernatant of the mutated strains, 
no metabolites with m/z values corresponding to kalim-
antacin or kalimantacin analogues with the expected AA 
substitutions could be detected (Fig. S1, S2).
Discussion and Conclusion
As a proof of concept, a Pseudomonas- specific code was 
created in this article for A domains. Since, as far as we 
know, no specificity- conferring codes for other genera 
have been published, it is difficult to compare this code 
with codes in other genera. However, when comparing 
the specificity- conferring code of the archetypic Phe- 
incorporating module of GrsA (DAWTIAAICK) with the 
presented code for use in Pseudomonas (DAPIMGGTCK), 
the difference between both codes is remarkable, with six 
out of 10 AA differing. Two of these six AA, at GrsA 
positions 301 and 322, are rather small changes, going 
from two times Ala to two times Gly, thus removing two 
small neutral groups out of the binding pocket. The other 
changes seem more drastic, as polar groups change into 
neutral groups or vice versa. It should be noted that 
changes do not necessarily imply drastic differences be-
tween codes in different genera. If the Pro- incorporating 
sequence is compared to the consensus sequence proposed 
by Stachelhaus and colleagues, only one of all AA is 
changed (from Tyr to Leu). As it goes with codon 
 optimization, it is possible that optimizing the specificity- 
conferring code, as is done here for Pseudomonas, improves 
the yield, but does not necessarily mean that a code from 
another organism does not give any result at all.
The bioassay of the positive control, showing wild- type 
activity again, proves the robustness of the method pre-
sented. Overall, this method is very efficient for the in 
gene replacement of active site sequences. Furthermore, 
chemical synthesis of the mutated DNA fragments 
 circumvents an elaborate targeted point mutation approach. 
Figure 2. Ligation independent cloning strategy. Flanking regions (350 bp and 500 bp) of the 10 AA containing active site were amplified from 
genomic DNA with tailed primers, introducing restriction sites that enabled restriction and ligation into the pUC18. After restriction with PstI, a 
mixture of linear plasmid DNA, amplified synthetic DNA fragment and T4 DNA polymerase was prepared, as proposed by Thieme et al. (2011). The 
mixture was incubated at 25°C for 5 min, and subsequently used for transformation of E. coli Top10 cells (Invitrogen™). Correct constructs were 
obtained with very high efficiencies (80–95%).
T4 DNA polymerase 
TGACCGGCTCTTGG
5’ flanking
CTGCA GGCAGGCCAATC
ACTGGCCGAGAACCG ACGTCCGTCCGGTTAG
CCGGCTCTTGGCA GGCAGGCCAA
GGCCGAGAACCGT CCGTCCGGTT
. . . . . ..... . . . . .
. . . . . ..... . . . . .
PstI
3’ flankingPstI
Synthetic fragment
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Therefore, this method is particularly suited for systematic 
in vivo analyses of mutated A domains.
All bioassays show a residual activity of both mutant 
strains and extracts, comparable to the batC deletion 
 mutant. Since LC- MS analyses show no detectable amounts 
of kalimantacin and it seems unlikely that all mutants 
produce the same kalimantacin intermediate as the batC 
knockout strain, this activity can only be explained by 
another, unrelated secondary metabolite produced by the 
P. fluorescens strain, with low but distinguishable activity 
against S. aureus ATCC27661. Additional bioassays against 
a collection of gram- positive and gram- negative strains 
showed that all mutant strains and the wild- type strain 
have a similar activity against different Pseudomonas strains 
(data not shown), indicating that other antibacterial sec-
ondary metabolites are indeed produced by P. fluorescens 
BCCM_ID9359.
There are a number of possible reasons why the kali-
mantacin biosynthetic assembly lines harboring the mutated 
A domains are no longer functional. First, the Pseudomonas- 
specific code might not be sufficiently adapted. However, 
all the critical conserved AA residues as proposed by 
Challis and colleagues (Challis et al. 2000) are present in 
each of the designed specificity- conferring codes. In vitro 
analysis of the specificity of the engineered A domains 
could shed more light on this. Furthermore, working in 
an in vivo system, downstream domains might not accept 
the alternative biosynthetic intermediates. Indeed, it has 
recently been shown that ketosynthase (KS) domains in 
trans- AT PKSs show specificity to the growing intermedi-
ate as well (Jenner et al. 2013). In addition, a recent 
paper by Kohlhaas and coworkers on the specificity in 
hybrid trans- AT PKS/NRPS clusters confirms that the AA- 
accepting KS domains possess a high specificity for NRPS- 
derived intermediates (Kohlhaas et al. 2013). In the 
kalimantacin cluster, this is expected to be the case for 
the KS domain of module 2 in Bat2. Engineering the 
substrate selectivity of this KS domain or replacing it 
with a KS domain that has an increased substrate toler-
ance could potentially resolve this issue. Not only the 
downstream domains could block synthesis, different stud-
ies have shown that the acceptor site of the C domain 
could also possess substrate selectivity (Belshaw et al. 1999; 
Ehmann et al. 2000). As such, it is possible that the A 
Figure 3. Bioassay with kalimantacin and analogues. (A). Halo formation by extracts of Pseudomonas fluorescens BCCM_ID9359 wild- type and 
mutant strains. 2 μL of crude extract was spotted on a lawn of S. aureus ATCC27661 (OD600 = 0.03) and incubated overnight at 37°C. (B). Halo 
formation by the wild- type and engineered strains. 2 μL of an overnight culture was spotted on a lawn of S. aureus ATCC27661 (OD600 = 0.03). 
Incubation at 16°C for 48 h allowed for growth of P. fluorescens BCCM_ID9359 (and mutant strains) and production of kalimantacin or analogues, 
followed by incubation at 37°C for 8 h for the growth of the lawn of S. aureus. WT, wild- type strain/extract; GA, kalimantacin with alanine instead 
of glycine; GL, kalimantacin with leucine instead of glycine; GV, kalimantacin with valine instead of glycine; GS, kalimantacin with serine instead of 
glycine; GC, kalimantacin with cysteine instead of glycine; GR, kalimantacin with arginine instead of glycine; GF, kalimantacin with phenylalanine 
instead of glycine; GD, kalimantacin with aspartic acid instead of glycine; GQ, kalimantacin with glutamine instead of glycine; GG, kalimantacin with 
glycine after reintroduction of the wild- type sequence in the gentamicin- resistant strain.
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domain is active, while the C domain is not accepting 
the alternative building block. This selectivity of the C 
domain was recently demonstrated by Calcott et al. (2014) 
in the pyoverdine synthetase PvdD in P. aeruginosa, and 
could also explain why the in vivo system in the P. fluo-
rescens strain in this study is blocked.
In this article, we present an efficient method to intro-
duce mutated active site sequences in the biosynthetic gene 
clusters. However, more insight is needed in the specificity 
of upstream and downstream domains to rationally engineer 
A domains in hybrid trans- AT PKS/NRPS clusters.
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